Deep-dives, mechanism breakdowns, and protocols for the compounds we carry. Strictly for qualified research use only.
Peptide Deep Dives
Both are once-weekly shots. Both cause major weight loss. So why did tirzepatide outperform semaglutide by nearly 50% in head-to-head trials? Here's the difference, in plain English.
Read article
Peptide Deep Dives
The longevity world has been obsessed with NAD+ for a decade. Here's what 113 clinical studies have actually figured out — and where they got stuck.
Read article
Industry News
While the world watched retatrutide, Novo Nordisk quietly filed for FDA approval of a different approach — combining two existing weight loss drugs into one weekly shot.
Read article
Industry News
71 pounds in 68 weeks. Eli Lilly's retatrutide just delivered the biggest weight loss numbers ever recorded in a Phase 3 trial — and it's only the first of eight readouts coming this year.
Read article
Industry News
In 2023, the FDA effectively killed access to BPC-157, GHK-Cu, and 17 others. In February 2026, that started reversing — but the headlines are missing the actual story.
Read article
Peptide Deep Dives
Your body makes a tiny molecule that helps your skin heal, your hair grow, and your tissue repair itself. By 60, you have less than half. Here's the 50-year story.
Read article